2. Home
  3. Conference Highlights
  4. SIU Congress 2017
  5. SIU 2017 Bladder Cancer

SIU 2017 Bladder Cancer

SIU 2017: Predicting Tumour Recurrence in Patients Treated with Bacillus Calmette-Guérin

Lisbon, Portugal (UroToday.com0 In this study, the authors attempt to use a urine based biomarker test to better identify BCG failures – they state that there is no good test to assess BCG failure at this time, thought TURBT remains the standard. They assess whether UroVysion FISH can identify early BCG failure, perhaps earlier than TURBT.

SIU 2017: Red Patches Seen during Endoscopic Surveillance of Bladder Cancer – When Should we Biopsy?

Lisbon, Portugal (UroToday.com) “Red patches” are a common finding on surveillance or initial cystoscopy that urologists are often concerned represent carcinoma-in-situ (CIS). However, bladder irritation, infection, or scope trauma can cause similar findings. 

In this study, the group from the UK retrospectively reviewed the charts of 4805 flexible cystoscopy reports over a 12 month period for the finding of “red patch.” Not every patient with the finding of “red patch” went on to biopsy, but they evaluate those that did.

SIU 2017: Factors Predicting Concomitant Carcinoma in Situ in Patients with Initially Diagnosed Non-Muscle Invasive Bladder Cancer

Lisbon, Portugal (UroToday.com) In this study, the authors assess the role of random bladder biopsies. While recent guidelines have already indicated the role of random bladder biopsies (typically in setting of positive cytology but negative cystoscopy, or in consideration of partial cystectomy), the authors complete a single institution assessment of predictors of positive bladder biopsies. 

SIU 2017: Results of Repeat Transurethral Resection of Bladder Tumor (TURBT) by Institution Performing the Initial TURBT: Comparative Analyses between Referred and Non-Referred Group

Lisbon, Portugal (UroToday.com) Repeat TURBT after an initial diagnosis of NMIBC, specifically high-grade T1 disease, is recommended by most guidelines. Due to moderate ~20-30% rate of understaging on initial TURBT, repeat TURBT is recommended to ensure that MIBC is not missed. However, considering the potential cost implications, patient discomfort, and potential risks of repeat TURBT, there has been renewed interest to reassess the need of repeat TURBT.

SIU 2017: Dynamic Real-Time Microscopy of Bladder Neoplasms Using Confocal Laser Endomicroscopy

Lisbon, Portugal (UroToday.com) In this study, the authors assess the role of random bladder biopsies. While recent guidelines have already indicated the role of random bladder biopsies (typically in setting of positive cytology but negative cystoscopy, or in consideration of partial cystectomy), the authors complete a single institution assessment of predictors of positive bladder biopsies. 

SIU 2017: Relation of ALDH1a and CD44 with Clinicopathological Factors in Transitional and Squamous Cell Carcinomas of Urinary Bladder

Lisbon, Portugal (UroToday.com) Cancer stem cells, usually representing a small 1-2% of the tumor volume, may be resistant to traditional therapy and may be a source of treatment resistant and disease progression. There are various CSC markers that are being evaluated for association with CSC presence and subsequently disease aggressiveness and treatment response. ALDH1a and CD44 are two such markers of CSC.

SIU 2017: Overexpression of Epidermal Growth Factor Receptor Predicts Bladder Cancer Local Aggressiveness

Lisbon, Portugal (UroToday.com)In this abstract, the authors examine the prognostive value of EGFR (epidermal growth factor receptor). EGF is important for cell proliferation, differentiation and invasion, and may contribute to tumorigenesis. It is often reported on IHC analysis in pathology reports for patients with bladder resections. The authors hypothesize that higher EGFR levels on IHC is associated with more aggressive bladder cancer.
Page 1 of 8